Rubitecan
From Self-sufficiency
Revision as of 16:48, 30 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s): antineoplastic-drug-stub)
| File:Rubitecan.png | |
| Systematic (IUPAC) name | |
|---|---|
|
(4S)-4-ethyl-4-hydroxy-11-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione | |
| Clinical data | |
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | 91421-42-0 |
| ATC code | none |
| PubChem | CID 11954380 |
| Synonyms | (19S)-19-ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione |
| Chemical data | |
| Formula | C20H15N3O6 |
| Molar mass | 393.349 g/mol[[Script error: No such module "String".]] |
Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.
History
On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, [1] and was accepted for filing on March 2004.[2]
On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,[3] and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.[4]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ "Drugs.com, SuperGen completes submission of New Drug Application (NDA) for Orathecin as an oral treatment for pancreatic cancer". Retrieved 2008-03-25.
- ↑ "Drugs.com, SuperGen's New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing". Retrieved 2008-03-25.
- ↑ "Drugs.com, SuperGen Announces Withdrawal of Orathecin NDA". Retrieved 2008-03-25.
- ↑ "Press release from the EMEA website regarding withdrawal of Orathecin MAA" (PDF). Retrieved 2008-03-25.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Cancer treatments
- Chemotherapeutic agents
- Antineoplastic and immunomodulating drug stubs
